Premium
Perturbations of Arginine Vasopressin Secretion during Inflammatory Stress: Pathophysiologic Implications
Author(s) -
CHIKANZA IAN C.,
PETROU PETROS,
CHROUSOS GEORGE
Publication year - 2000
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2000.tb05448.x
Subject(s) - endocrinology , medicine , vasopressin , tumor necrosis factor alpha , inflammation , hypothalamus , prolactin , secretion , hormone
A bstract : Pro‐inflammatory cytokines, such as interleukin‐1β (IL‐1β, interleukin‐6 (IL‐6), and tumor necrosis factor‐α (TNFα), released from inflammatory foci, can activate the hypothalamus to produce corticotrophin‐releasing hormone (CRH) and arginine vasopressin (AVP). These hypothalamic peptides in synergy increase ACTH production by the pituitary gland and hence corticosteroid (CS) secretion by the adrenal cortices. CS dampens inflammation. The pituitary also produces prolactin (PRL), which is pro‐inflammatory, and macrophage inhibitory factor (MIF), which by counteracting the anti‐inflammatory and immunosuppressive effects of CS, is pro‐inflammatory. Lewis rats develop a variety of induced‐autoimmune inflammatory conditions, such as streptococcal cell wall arthritis, whereas the histocompatible F344 Fisher rats are resistant to this condition. Lewis rats have a defective hypothalamic‐pituitary adrenal (HPA) response to a variety of hypothalamic stimuli, but have augmented systemic secretion of AVP. Patients with rheumatoid arthritis (RA) have deficient CS with exaggerated PRL responses to inflammatory stimuli. Within inflammatory foci, CRH is pro‐inflammatory. AVP, which augments autologous mixed lymphocyte reactions, can replace the IL‐2 requirement for γIFN production by T cells via V 1a receptors, and potentiates primary antibody responses, is also pro‐inflammatory. Lewis rats have significantly high plasma levels, hypothalamic content, and in vitro release of AVP in comparison to the inflammatory disease‐resistant Fischer rats. Immunoneutralization of AVP attenuates inflammatory responses. In Sprague‐Dawley rats, AVP potentiates PRL secretion. Preliminary studies in patients with RA have shown that the circulating levels of AVP are significantly increased, which might be a compensatory response to low CS levels or a result of elevated levels of IL‐6 in these patients but could nevertheless contribute to rheumatoid inflammation. A similar observation has been made in patients with ankylosing spondylitis.